Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Paclitaxel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paclitaxel SCHEMBL13622863 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL15590870 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL759366 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL12929005 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760447 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL18389589 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760443 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL10122072 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL13241436 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL22149786 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 393486 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119191366-A | Doped magnetic nano particle and preparation method and application thereof | 中国科学院精密测量科学与技术创新研究院 | 2024-12-27 | — | — | CN | claimed |
| US-12173039-B1 | TPL2 inhibiting agents, uses thereof, and detection of TPL2 | WASHINGTON UNIVERSITY (US) | 2024-12-24 | — | — | US | claimed |
| US-20240415982-A1 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENT | SERVICIO ANDALUZ DE SALUD (ES) | 2024-12-19 | — | — | US | claimed |
| EP-4475955-A1 | TREATMENT OF CANCER | Immutep S.A.S. (FR) | 2024-12-18 | — | — | EP | claimed |
| EP-4475895-A1 | LOCALLY ADMINISTERED COMPOSITIONS AND METHODS OF USE THEREOF | Fairleigh Dickinson University (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2024250427-A1 | VINCAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 西南大学 | 2024-12-12 | — | — | WO | claimed |
| US-20240408071-A1 | NOVEL COMBINATION OF SEROTONIN RECEPTOR (5-HTR2B) ANTAGONIST AND AN IMMUNOMODULATOR AND CHEMOTHERAPEUTIC DRUGS FOR INHIBITION OF CANCER | NATIONAL CENTRE FOR CELL SCIENCE (IN) | 2024-12-12 | — | — | US | claimed |
| US-20240409655-A1 | ANTI-OX40 ANTIBODIES AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-12-12 | — | — | US | claimed |
| US-20240408175-A1 | BMP9 OR AN AGONIST THEREOF AND ITS USES RELATED TO REDUCING METASTASIS OF CANCER | THE UAB RESEARCH FOUNDATION (US) | 2024-12-12 | — | — | US | claimed |
| WO-2024254103-A1 | TGFB2-IRF5 THERAPEUTICS FOR CANCER | GMP BIOTECHNOLOGY LIMITED (CN) | 2024-12-12 | — | — | WO | claimed |
| EP-0253738-B1 | TAXOL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC SANTE (FR) | 1990-01-31 | — | — | EP | claimed |
| EP-0336840-A1 | Process for the preparation of taxol | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1989-10-11 | — | — | EP | claimed |
| EP-0253739-B1 | PROCESS FOR THE PREPARATION OF TAXOL AND OF DESACETYL-10-TAXOL | RHONE-POULENC SANTE (FR) | 1989-10-11 | — | — | EP | claimed |
| WO-1989008453-A1 | NEW, WATER SOLUBLE, ANTINEOPLASTIC DERIVATIVES OF TAXOL | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-09-21 | — | — | WO | claimed |
| US-4857653-A | Process for the preparation of taxol and 10-deacetyltaxol | RHONE-POULENC SANTE (FR) | 1989-08-15 | — | — | US | claimed |
| US-4814470-A | Taxol derivatives, their preparation and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1989-03-21 | — | — | US | claimed |
| EP-0253738-A1 | Taxol derivatives, their preparation and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1988-01-20 | — | — | EP | claimed |
| EP-0253739-A1 | Process for the preparation of taxol and of desacetyl-10-taxol | RHONE-POULENC SANTE (FR) | 1988-01-20 | — | — | EP | claimed |
| WO-1986003007-A1 | ASSAY FOR THE DETECTION OF EPIGENETIC TOXIC SUBSTANCES | CHOU IIH NAN | 1986-05-22 | — | — | WO | claimed |
| EP-0174810-A2 | Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein DNA | HSC Research Development Corporation (CA) | 1986-03-19 | — | — | EP | claimed |